Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomised, double-blind, placebo-controlled, 4-period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 g, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids
fluticasone propionate
NSG110341
NCT00848965
Rhinitis, Allergic, Perennial
Phase 4
 
May 2013

Powered by ideaPoint, Inc.